Department of Medicine, Clinical Pharmacology Unit, Karolinska University Hospital (Solna)
Stockholm, 171 76, Sweden
NCT Number: NCT01035320
The purpose of this study is compare the effects of simvastatin+ezetimibe with those of simvastatin alone on platelet activity, platelet-leukocyte interactions and inflammatory variables in diabetic patients with or without impaired renal function.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 4
Stockholm, 171 76, Sweden
A detailed study protocol is available.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
Other names: Simvastatin, Ezetrol
Time frame: 6 weeks, 14-18 weeks, 22-24 weeks
Time frame: 6 weeks, 14-18 weeks, 22-24 weeks
Karolinska Institutet
Other
Acronym: PLAUDIT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03242343
Aneurysm, Arterio-venous Fistula
Birmingham, Alabama, United States
View Trial DetailsNCT00001859
Diabetes Mellitus, Endocrine System Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT03952819
Diabetes Mellitus, Endocrine System Diseases
Bolu, Merkez, Turkey (Türkiye)
View Trial DetailsNCT03157414
Diabetes Mellitus, Endocrine System Diseases
Oslo, Norway
View Trial Details